Amyloid-ß-directed immunotherapy for Alzheimer's disease (Q34548700)

2 August 2017

6 references

25 April 2019

20 June 2019

25 June 2019

20 November 2019

15 December 2019

9 September 2020

Amyloid-ß-directed immunotherapy for Alzheimer's disease (English)

1 reference

2 August 2017

6 references

25 April 2019

20 June 2019

25 June 2019

20 November 2019

15 December 2019

9 September 2020

1 reference

20 November 2019

1 reference

15 December 2019

2 references

9 September 2020

L Lannfelt

1

1 reference

2 August 2017

N R Relkin

series ordinal

2

1 reference

2 August 2017

E R Siemers

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 March 2014

6 references

Journal of Internal Medicine

2 August 2017

25 April 2019

20 June 2019

25 June 2019

20 November 2019

15 December 2019

6 references

2 August 2017

25 April 2019

20 June 2019

25 June 2019

20 November 2019

15 December 2019

275

1 reference

2 August 2017

3

1 reference

2 August 2017

284-295

1 reference

Creative Commons Attribution 3.0 Unported

2 August 2017

6 references

25 April 2019

20 June 2019

25 June 2019

20 November 2019

15 December 2019

on focus list of Wikimedia project

9 September 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Large aggregates are the major soluble Aβ species in AD brain fractionated with density gradient ultracentrifugation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Alzheimer's disease: clinical trials and drug development

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Active and passive immunotherapy for neurodegenerative disorders

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Sensitive ELISA detection of amyloid-beta protofibrils in biological samples

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Internalized antibodies to the Abeta domain of APP reduce neuronal Abeta and protect against synaptic alterations.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

The Arctic Alzheimer mutation favors intracellular amyloid-beta production by making amyloid precursor protein less available to alpha-secretase

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Clearing amyloid through the blood-brain barrier

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Biophysical methods for the determination of antibody-antigen affinities

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238820

Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity.

7 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12168

The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12168

Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12168

Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12168

RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12168

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12168

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12168

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12168

Measurement of anti-beta amyloid antibodies in human blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12168

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12168

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12168

An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12168

Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12168

21 January 2018

Identifiers

DOI

10.1111/JOIM.12168

1 reference

2 August 2017

1 reference

2 August 2017

1 reference